posted on 2023-03-31, 04:24authored byJan M. Pawlicki, David L. Cookmeyer, Damian Maseda, John K. Everett, Fang Wei, Hong Kong, Qian Zhang, Hong Y. Wang, John W. Tobias, David M. Walter, Kelly M. Zullo, Sarah Javaid, Amanda Watkins, Mariusz A. Wasik, Frederic D. Bushman, James L. Riley
Supplemental Figures and Tables
Funding
Penn Center for AIDS Research
Cancer Center Human Immunology Core
NIH
History
ARTICLE ABSTRACT
Fusion genes including NPM–ALK can promote T-cell transformation, but the signals required to drive a healthy T cell to become malignant remain undefined. In this study, we introduce NPM–ALK into primary human T cells and demonstrate induction of the epithelial-to-mesenchymal transition (EMT) program, attenuation of most T-cell effector programs, reemergence of an immature epigenomic profile, and dynamic regulation of c-Myc, E2F, and PI3K/mTOR signaling pathways early during transformation. A mutant of NPM–ALK failed to bind several signaling complexes including GRB2/SOS, SHC1, SHC4, and UBASH3B and was unable to transform T cells. Finally, T-cell receptor (TCR)–generated signals were required to achieve T-cell transformation, explaining how healthy individuals can harbor T cells with NPM–ALK translocations. These findings describe the fundamental mechanisms of NPM–ALK-mediated oncogenesis and may serve as a model to better understand factors that regulate tumor formation.
This investigation into malignant transformation of T cells uncovers a requirement for TCR triggering, elucidates integral signaling complexes nucleated by NPM–ALK, and delineates dynamic transcriptional changes as a T cell transforms.See related commentary by Spasevska and Myklebust, p. 3160